Brukinsa® reduces the number of cancer cells and delays the worsening of the disease.

Exclusive medicines are those for which there is no competition because the patent of the laboratories that supply them has not yet expired.

The Consell de Govern has authorised the purchase of the exclusive drug zanubrutinib – under the trade name Brukinsa®, marketed by Beigene Esp, SL, in the form of capsules containing 80 mg – for use in Health Service centres, for a value of 2,625,549.96 euros.

TDB keeps you informed. Follow us on: Facebook, Twitter and Instagram

Salud contracts the supply of a unique drug for the treatment of certain types of cancer

Exclusive medicines are those for which there is no competition because the patents of the laboratories supplying them have not yet expired.

Zanubrutinib is an active substance used in the treatment of cancer. It belongs to a class of drugs called ‘protein kinase inhibitors’ and works by blocking an inhibitor of Bruton’s tyrosine kinase, a protein in the body that helps cancer cells grow and survive. By blocking it, it reduces the number of cancer cells and slows the cancer from getting worse.

Brukinsa® is used to treat Waldeström’s macroglobulinaemia (also known as ‘lymphoplasmacytic lymphoma’). This medicine is used when the disease has relapsed or treatment has not worked or in patients who cannot receive chemotherapy together with an antibody. It is also used to treat marginal zone lymphoma, a type of cancer that also affects B-lymphocytes or B-cells, and is used in cases of recurrence or when treatment has not worked. It is also used to treat chronic lymphocytic leukaemia, another type of slow-growing B-cell cancer that affects the lymph nodes, and follicular lymphoma.